Associations of remission status and lanreotide treatment with quality of life in patients with treated acromegaly

European Journal of Endocrinology

Volumn 155, Issue 6, 2006, Pages 831-837

  Hua, Shih Che ^a   Yan, Yuan Horng ^a   Chang, Tien Chun ^b  

^a CHIA YI CHRISTIAN HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; GLUCOCORTICOID; SEX HORMONE; THYROXINE;

ACROMEGALY; ADRENAL INSUFFICIENCY; ADULT; AGED; ARTICLE; CHINESE; CONTROLLED STUDY; FEMALE; HORMONE SUBSTITUTION; HUMAN; HYPOPHYSIS ADENOMA; HYPOPITUITARISM; HYPOTHYROIDISM; LANGUAGE; MAJOR CLINICAL STUDY; MALE; MICROADENOMA; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; QUALITY OF LIFE; QUESTIONNAIRE; REMISSION; SCORING SYSTEM;

ACROMEGALY; ADULT; AGED; ANTINEOPLASTIC AGENTS; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; REMISSION INDUCTION; SOMATOSTATIN;

EID: 33845980194     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.1.02292     Document Type: Article

References (25)

1. Melmed S. Acromegaly. New England Journal of Medicine 1990 322 966-977.
2. Etxabe J, Gaztambide S, Latorre P & Vazquez JA. Acromegaly: an epidemiological study. Journal of Endocrinological Investigation 1993 16 181-187.
3. Alexander L, Appletton D, Hall R, Ross WM & Wilkinson R. Epidemiology of acromegaly in the Newcastle region. Clinical Endocrinology 1980 12 71-79.
4. Orme SM, McNally RJ, Cartwright RA & Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. Journal of Clinical Endocrinology and Metabolism 1998 83 2730-2734.
5. Swearingen B, Barker FG, II, Katznelson L, Biller BM, Grinspoon S, Klibanski A, Moayeri N, Black PM & Zervas NT. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly, Journal of Clinical Endocrinology and Metabolism 1998 83 3419-3426.
6. Wright AD, Hill DM, Lowy C & Fraser TR. Mortality in acromegaly. Quarterly Journal of Medicine 1970 39 1-16.
7. Bates AS, Vant Hoff W. Jones JM & Clayton RN. An audit of outcome of treatment in acromegaly. Quarterly Journal of Medicine 1993 86 293-299.
8. Abosch A, Tyrrell JB, Lamborn KR, Haneegan LT, Applebury CB & Wilson CB. Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcomes and long-term results. Journal of Clinical Endocrinology and Metabolism 1998 83 3411-3418.
9. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K & Melmed S. Criteria for cure of acromegaly: a consensus statement. Journal of Clinical Endocrinology and Metabolism 2000 85 526-529.
10. Webb SM, Prieto L, Badia X, Albareda M, Catalá M, Gaztambide S, Lucas T, Páramo C, Picó A, Lucas A, Halperin I, Obiols G & Astorga R. Acromegaly quality of life questionnaire (ACROQOL), a new health-related quality of life questionnaire for patients with acromegaly: development and psychometric properties. Clinical Endocrinology 2002 57 251-258.
11. Badia X, Webb SM, Prieto L & Lara N. Acromegaly quality of life questionnaire (AcroQoL). Health and Quality of Life Outcomes 2004 27 2-13.
12. Webb SM, Páramo C, Astorga R, Picó A, Gómez JM, de Pablos P, Benito P, Varela C, Lucas-Morante T, Moreno B, Catalá M, Gaztambide S, Halperin I, Torres E, Lucas A, Badia X & Gilabert M. Longitudinal study of health-related quality of life (HR-QoL) in acromegaly, evaluated with the Acroqol Questionnaire 11th Meeting of the European Neuroendocrine Association ENEA Oral Communication, Munich, Germany 2004.
13. Rowles SV, Prieto L, Badia X, Shalet SM, Webb SM & Trainer PJ. Quality of life (QOL) in patients with acromegaly is severely impaired: use of a novel measure of QOL: acromegaly quality of life questionnaire. Journal of Clinical Endocrinology and Metabolism 2005 90 3337-3341.
14. Herdman M, Fox-Rushby J & Badia X. A model of equivalence in the cultural adaptation of HRQoL instruments: the universalist approach. Quality of Life Research 1998 7 323-335.
15. Ezzat S, Snyder PJ, Young WF, Boyajy LD, Newman C, Klibanski A, Molitch ME, Boyd AE, Sheeler L, Cook DM, Malarkey WB, Jackson I, Vance ML, Thorner MO, Barkan A, Frohman LA & Melmed S. Octreotide treatment of acromegaly. A randomized, multicenter study. Annals of Internal Medicine 1992 117 711-718.
16. Flogstad AK, Halse J, Haldorsen T, Lancranjan I, Marbach P, Bruns C & Jervell J. Sandostatin LAR in acromegalic patients: a dose-range study. Journal of Clinical Endocrinology and Metabolism 1995 80 3601-3607.
17. Arosio M, Macchelli S, Rossi CM, Casati G, Biella O & Faglia G. Effects of treatment with octreotide in acromegalic patients - a multicenter Italian study. Italian Multicenter Octreotide Study Group. European Journal of Endocrinology 1995 133 430-439.
18. Suliman M, Jenkins R, Ross R, Powell T, Battersby R & Cullen DR. Long-term treatment of acromegaly with the somatostatin analogue SR-lanreotide. Journal of Endocrinological Investigation 1999 22 409-418.
19. Giusti M, Ciccarelli E, Dallabonzana D, Delitala G, Faglia G, Liuzzi A, Gussoni G & Giordano DG. Clinical results of long-term slow-release lanreotide treatment of acromegaly. European Journal of Clinical Investigation 1997 27 277-284.
20. Woodhouse LJ, Mukherjee A, Shalet SM & Ezzat S. The influence of growth hormone status on physical impairments, functional limitations, and health-related quality of life in adults. Endocrine Reviews 2006 27 287-317.
21. Sonino N, Scarpa. E, Paoletta A, Fallo F & Boscaro M. Slow-releasing lanreotide treatment in acromegaly: effects on quality of life. Psychotherapy and Psychosomatics 1999 68 165-167.
22. Gilbert J, Ketchen M, Kane P, Mason T, Baister E, Monaghan M, Barr S & Harris PE. The treatment of de novo acromegalic patients with octreotide-LAR: efficacy, tolerability and cardiovascular effects. Pituitary 2003 6 11-18.
23. Trepp R, Everts R, Stettler C, Fischli S, Allemann S, Webb SM & Christ ER. Assessment of quality of life in patients with uncontrolled vs controlled acromegaly using the Acromegaly Quality of Life Questionnaire (AcroQoL). Clinical Endocrinology 2005 63 103-110.
24. Rowles SV, Prieto L, Badia X, Shalet SM, Webb SM & Trainer PJ. Quality of life (QOL) in patients with acromegaly is severely impaired: use of a novel measure of QOL: acromegaly quality of life questionnaire. Journal of Clinical Endocrinology and Metabolism 2005 90 3337-3341.
25. Damjanovic SS, Neskovic AN, Petakov MS, Popovic V, Macut D, Vukojevic P & Joksimovic MM. Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure? Clinical Endocrinology 2005 62 410-417.